Frexalimab

DB18926InvestigationalProtein Based Therapies

Frexalimab is under investigation in clinical trial NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis).

Mechanism: Pharmacologically active on CD40 ligand
Curator reviewed
Also known as: Immunoglobulin G1 (272-arginine,325-alanine), anti-(human CD40 ligand) (human-mus musculus monoclonal SAR441344 gamma1-chain), disulfide with human-mus musculus monoclonal SAR441344 kappa-chain, dimer
Code names: INX 021 · INX 021-56 · SAR-441344 · XC 01129

Resolves to

Compound

UNIIWO7SFK0ENJCAS2515463-86-0

Targets

P29965CD40LG

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Frexalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account